Phase 4 RCT of 608 adults with chronic migraine and medication-overuse headache, all given brief education: eptinezumab 100 mg IV reduced monthly migraine days in weeks 1–4 more than placebo (−6.9 vs −3.7; difference −3.2); adverse events 41.9% vs 36.9%.
RCTn = 608
Jensen et al. Eptinezumab With Patient Education for Chronic Migraine and Medication-Overuse Headache: The Randomized, Placebo-Controlled RESOLUTION Trial